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ABSTRACT  We  immunocytochemically  stained  rat  pituitary  glands  using  antibodies  against 
plasminogen  activators  of  the  tissue  type  (t-PA)  and  the  urokinase  type  (u-PA).  A  large 
population  of endocrine cells  in the anterior lobe of the gland displayed intense cytoplasmic 
immunoreactivity  with anti-t-PA.  In some areas of the  intermediate  lobe we found  a weak 
staining,  and we observed weakly staining granular structures  in the posterior lobe. Controls 
included  absorption  of  the  antibodies  with  highly  purified  t-PA.  In  addition,  SDS  PAGE 
followed  by  immunoblotting  of  pituitary  gland  extracts  revealed  only  one  band  with  an 
electrophoretic  mobility  similar  to  that  of t-PA when  stained  with  anti-t-PA  IgG.  No  u-PA 
immunoreactivity  was  detected  in  the  rat  pituitary  gland.  Sequential  staining  experiments 
using antibodies against growth hormone and t-PA demonstrated that the t-PA-immunoreac- 
tive  cells  constitute  a  large  subpopulation  of the  growth  hormone-containing  cells.  These 
findings  represent the first direct evidence for the presence of t-PA in cell types other than 
endothelial  cells  in the intact normal organism.  In this article we discuss  the  implications  of 
the results for a possible  role of t-PA in the posttranslational  processing of prohormones. 
Plasminogen activators are serine proteases, able to convert 
the proenzyme plasminogen into the active protease plasmin. 
It is well  documented  that  there  are  at least two types of 
mammalian plasminogen activators. The two types that can 
be distinguished by differences in molecular weight (Mr) and 
immunological reactivity (for reviews see references 1-4) are 
products of different genes (5-8).  Both  the  urokinase-type 
plasminogen activator (u-PA), ~  Mr ~  50,000, and the tissue- 
type plasminogen activator (t-PA), Mr ~  70,000, are secreted 
from cells in culture as partly or completely inactive proen- 
zymes (9-12), and it is generally believed that they exert their 
biological functions by activation of extracellular plasmino- 
gen. 
Production and release ofplasminogen activators have been 
implicated in thrombolysis (for reviews see references 2 and 
3) and a variety of biological processes involving tissue deg- 
radation (for reviews see references 4  and  13), for example 
Abbreviations used in this paper. TBS, 0.05 M Tris-HC1, pH 7.4, 
containing 0.15 M NaCl; t-PA, tissue-type plasminogen activator; 
u-PA, urokinase-type plasminogen activator. 
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the postlactational involution of the  mammary gland (14), 
ovulation (15),  implantation of the fertilized ovum (16,  17), 
inflammation  (18),  and  cancer  (4,  13,  19-21).  A  role  of 
plasminogen activators in the processing of prohormones has 
also been proposed (22-24).  u-PA seems to be the type of 
plasminogen  activator  involved  in  tissue  degradation  (for 
review see reference 4),  whereas t-PA  until  now has been 
linked primarily with thrombolysis (3). 
Recent  immunocytochemical  studies  have  shown  that 
u-PA immunoreactivity is widely distributed in the normal 
mouse. Most notably, u-PA was found in widely disseminated 
connective tissue cells with a fibroblast-like morphology that 
occurred in high numbers in the lamina propria of the gas- 
trointestinal tract and to a lesser extent in a number of other 
organs, u-PA immunoreactivity was also found in the epithe- 
lial cells  of the proximal and distal kidney tubules and the 
ductus deferens, pulmonary pneumocytes, decidual  cells  of 
the  placenta,  and  epithelial  cells  of involuting  mammary 
glands, whereas no immunoreactivity was found in endothe- 
lial  cells (25).  Strong u-PA immunoreactivity has also been 
305 demonstrated in invasively growing areas of the murine Lewis 
lung carcinoma (21). 
t-PA immunoreactivity has been demonstrated in endothe- 
lial cells of veins and other blood vessels of several human 
tissues (26), but no systematic immunocytochemical studies 
on the occurrence of t-PA in the intact organism have been 
reported. We now report that t-PA immunoreactivity is pres- 
ent in endocrine cells of intact rat pituitary glands and that 
these cells constitute a  large subpopulation of the cells that 
contain growth hormone immunoreactivity. 
MATERIALS  AND  METHODS 
Materials:  We  obtained  the  following  materials from the  indicated 
sources:  protein-A  Sepharose  and  cyanogen  bromide-activated  Sepharose 
(Pharmacia Fine Chemicals, Uppsala, Sweden);  swine IgG anti-rabbit immu- 
nnglobulins, rabbit peroxidase-anti-peroxidase  complexes and peroxidase-cou- 
pied swine lgG anti-rabbit immunoglobulins (Dakopatts, Copenhagen); per- 
oxidase-coupled protein A  (Amersham International, Amersham, U.IC); o- 
phenylenediamine and Tween 20 (Merck A.G. Darmstadt); 3-amino-9-ethyl- 
carbazole  (Sigma Chemical Co.,  St.  Louis, MO);  lmmunoplate I  (NUNC, 
Rosldlde, Denmark); bovine serum albumin (BSA; Behring, Warbutg, Federal 
Republic of Germany); and Millipore nitrocellulose sheets GSWP 00010 (Mil- 
lipore,  Bedford,  MA). All other materials were those described previously (9, 
10, 12, 21, 25-3 l) or of the best commercially available grade. 
Animals:  Male (unless otherwise stated) Wistar rats, 300-350 g, were 
anesthetized with diethylether and fixed by intracardiac perfusion with -60 ml 
cold (4°C) 0.01 M sodium phosphate, pH 7.4, with 0.14 M NaCI (PBS) followed 
by -60 ml cold (4°C) 1% (wt/vol) paraformaldehyde solution in 10 mM sodium 
phosphate buffer, pH 7.4. Alternatively, tissue was removed from diethylether- 
anesthetized animals without any preceding peffusion and immediately frozen 
in isopentane on dry ice.  Tissue used for zymographic or immunoblotting 
analysis was removed from animals perfused with -60 ml of PBS after dieth- 
ylether anesthesia. 
Tissue Treatment:  For immunocytochemistry, pituitary #ands were 
dissected from animals perfused with paraformaldehyde and postfixed for 14- 
16 h at 4°C, then rinsed for 4-6 h in 0.1 M sodium phosphate buffer, pH 7.4, 
containing 20% (wt/vol) sucrose. Pituitary glands were then frozen in melting 
Freon  13 and cryostat sections (6-8 #m) were cut at -20"C and collected  on 
chrome alum-gelatine-coated slides. 
For zymographic and immunoblotting analysis freshly PBS-perfused  pitui- 
tary glands were washed with PBS, blotted dry on filter paper, weighed, minced, 
and homogenized with 75 mM potassium acetate buffer, pH 4.2,  containing 
0.3 M sodium chloride,  0.1 M L-arginine,  10 mM EDTA, and 0.25%  (wt/vol) 
Triton X-100 (32),  10 ul/mg wet weight. The extracts were centrifuged (16,000 
g) at 4"C for  10 min and the superuatants were stored frozen (-20°C) until 
analysis. 
Enzyme-linked Immunosorbent Assay:  lmmunoplates  were 
coated overnight at 37"C with 2 ug/ml of antigen or BSA in 0.1  M  Na2CO3, 
pH 9.8,  100 izl/well. The plates were washed and the remaining protein-binding 
sites were blocked by incubation with 200 ~1 0.25%  (wt/vol) BSA in PBS. The 
primary  antibody  under investigation was added  (100  ~l/well).  Usually a 
fivefold  serial  dilution, made with PBS containing 0.1% (wt/vol) Tween 20 
(PBS-Twccn)  starting from l0 vg/ml, was used. The plate was washed again 
and incubated with peroxidase-linked swine IgG anti-rabbit immunnglobulins, 
diluted 1:800 in PBS-Tween,  100/~l/well.  After washing was done with PBS- 
Tween and once with distilled H=O, the peroxidase reaction was performed for 
5 min with 0.1% o-phenylenediamine,  0.01% H202 in 0.1 M citrate-phosphate 
buffer, pH 5.0,  100 ul/well. The reaction was stopped by adding 100 ~1 1 M 
H2SO4, and the absorbance was read at 492 nm with a Dynatech Microelisa 
Minireader (Dynatech, Alexandria, VA).  Incubation with  first  and second 
antibody layer was performed at 37"C for I h while shaking. All other procedures 
were done at room temperature. All washings were performed four times with 
PBS-Tween unless otherwise stated. Controls included wells coated with BSA 
to exclude nonspecific binding of the first antibody layer, and the absorbance 
readings of wells without the first antibody layer were subtracted. 
Antibodies:  Rabbit antibodies against human t-PA were produced by 
immunization of rabbits with t-PA purified by affinity chromatography using 
a  monoclonal antibody as described (26,  31). Preimmune and immune IgG 
were purified by affinity chromatography on protein A-Sepharose (31), and the 
IgG concentration was determined by absorbance measurement at 280 nm 
using an extinction coefficient E~lm  ~  of 13.7. The enzyme-linked immunosor- 
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bent assay showed that the rabbit antibodies raised against human t-PA reacted 
with the mouse monoclonal anti-t-PA IgG that had been used for purification 
of the human t-PA. We found no reaction when we used prcimmune IgG from 
the same rabbit.  The presence of these contaminating antibodies was therefore 
probably due to trace amounts  of monoclonal antibody leaking from the affinity 
chromatography column during the elution of human t-PA. The rabbit anti-t- 
PA antibodies used in this study were therefore absorbed by passing 2.2 nag 
anti-t-PA IgG through a PBS..equilibrated  column (2 ml) with ~2 mg mono- 
clonal antibody coupled to cyanogen bromide-activated Sepharose. The rabbit 
anti-human t-PA IgG did not cross-react with human u-PA (26), but various 
findings (see Results) indicated that they cross-reacted with rat t-PA. Rabbit 
IgG antibodies against highly purified mouse u-PA were produced, purified, 
and absorbed with a glutaraldehyde polymer of mouse proteins depleted of u- 
PA as described (25, 28). We previously reported that the rabbit anti-mouse u- 
PA did not cross-react with mouse t-PA, whereas it cross-reacted with rat u-PA 
(25). Swine IgG anti-rabbit immunoglobulin was absorbed by incubating 1 ml 
of the IgG preparation with 50 #1 rat serum for 20 h at 4°C, which was then 
centrifuged (100,000 g) at 4°C for 60 rain. 
For the sequential staining experiments rabbit antibodies directed against 
human growth hormone (NIADDK-anti-hGH-IC-2) and ACTH (NIADDK- 
anti-hACTH-IC-  1) were kindly donated by the National Hormone and Pituitary 
Program of the National  Institute of Arthritis, Diabetes and Digestive  and 
Kidney Diseases, Bethesda, MD. 
Immunocytochemistry:  Cryostat  sections  of  fixed  tissue  were 
washed with 0.05 M  Tris-HCl, pH 7.4,  with 0.15 M  NaCI (TBS) containing 
1% (wt/vol) Triton X-100 (TBS-Triton) for  15 rain, incubated with 1% (wt/ 
vol) human serum albumin in TBS for 30 rain, briefly rinsed in TBS-Triton, 
and incubated with different concentrations of antibodies. We found optimal 
staining with concentrations of 4-10 ~g IgG/ml when an 18 h incubation at 
4°C was used followed by a  1 h re-equilibration at room temperature. The site 
of the antigen-antibody reaction was demonstrated by sequential incubation 
with swine lgG anti-rabbit immunoglobulin (diluted h30), horseradish perox- 
idasc-coupled protein A (diluted 1:200), and rabbit peroxidase-antiperoxidase 
complexes (diluted 1:70), each for 30 rain at room temperature, with intense 
washing with TBS-Triton between each incubation period.  All antibody dilu- 
tions were performed with TBS containing 0.25% BSA. Peroxidase activity was 
demonstrated with  diaminobenzidine-H202 (29)  and  sections were  lightly 
counterstained with baematoxylin. 
Controls were as recommended by Sternberger  (33) and included (a) omis- 
sion of first or second layer of antibodies or omission of peroxidase-coupled 
protein A and peroxidase-antiperoxidase  complexes,  (b) substitution of  primary 
antibodies by preimmune IgG from the same rabbit, and (c) absorption of the 
antibodies with the corresponding  antigen. Absorption with t-PA and u-PA was 
performed by passing the IgG preparations twice through Sepharose columns 
(1 ml) coupled with highly purified preparations of human t-PA (see reference 
10) and mouse u-PA (see reference 27), respectively.  As a control, aliquots of 
the respective IgG preparations were  passed twice  through similar columns 
coupled with the same amount of BSA. All columns were equilibrated with 
TBS and developed by gravity.  Enzyme-linked immunosorbent analysis with 
human t-PA as antigen demonstrated that the concentration of t-PA-absorbed 
anti-t-PA needed to  obtain  identical absorbance readings was ~3,000-fold 
higher than that needed of nonabsorbed anti-t-PA IgG. 
For  the sequential staining experiments, cryostat sections were  initially 
stained for t-PA as described  above, except that the peroxidase activity was 
demonstrated with 3-amino-9-ethylcarbazole (29). After photography the per- 
oxidase reaction product was eluted with ethanol, and antibodies bound to the 
sections  were removed by oxidation as described (30, 34). Thereafter incubation 
of each section with swine IgG anti-rabbit immunoglobulin  and rabbit pe~ox- 
idase-antiperoxidas¢ complexes was followed  by development with 3-amino- 
9-ethylcarbazole  to  ensure the efficiency  of the antibody elution.  Sections 
completely negative after this development were  then processed for staining 
with rabbit anti-human growth hormone or rabbit anti-human ACTH, diluted 
1/100-1/250 using a  30-min incubation at room temperature. This was fol- 
lowed by incubation with swine IgG anti-rabbit immunoglobulins, and rabbit 
peroxidase-antiperoxidase complexes and the sections were developed with 
diaminobenzidine-H202 as described above. 
Electophoresis and Immunoblotting:  SOS  PAGE and electro- 
phoretic transfer of the proteins to  nitrocellulose  paper were  performed as 
described (25). The nitrocellulose  paper was air dried and fixed in 1% (wt/vol) 
paraformaldehyde in l0 mM sodium phosphate buffer, pH 7.4, for 1 h at 4°C. 
Immunocytochemical staining of the nitrocellulose  replicas  was performed 
identically to the staining of tissue sections, except that the washing with TBS- 
Triton was done at 370C. We performed zymographic analysis for plasminngen 
activators of tissue extracts separated by SDS PAGE as described (27, 35), by 
layering the polyacrylamide gel on a  flbrin-agarose gel with or without plas- 
minogen. Marker proteins were as described (9,  10). RESULTS 
Immunocytochemical Findings 
Immunocytochemical staining of rat pituitary glands with 
anti-t-PA revealed immunoreactivity in a  number of endo- 
crine cells in the anterior lobe of the rat pituitary gland (Fig. 
1).  Some of the  cells were intensively stained,  and  others 
stained more weakly. Some endocrine cells of the anterior 
lobe contained no detectable immunoreactive material. The 
t-PA-immunoreactive material was located solely in the cy- 
toplasm of  the cells, often with a distinct granular appearance 
(Fig. 2). In some areas of the pars intermedia of rat pituitary 
gland we found a weak staining (result not shown), and in 
other areas we observed no immunoreactivity (Fig.  l). The 
posterior lobe contained many small areas, with apparently 
granular  weak immunoreactivity (Fig.  1).  To evaluate the 
possibility that the histological location oft-PA was somewhat 
altered during the perfusion fixation, rat pituitary glands were 
excised and frozen in isopentane on dry ice. Sections were 
thawed in  1% (wt/vol) paraformaldehyde in  l0 mM sodium 
FIGURE  I  Rat pituitary gland stained with antiserum to t-PA. Sections were incubated with rabbit anti-human t-PA IgG absorbed 
with Sepharose-coupled BSA (left) or purified human t-PA (right).  Note the presence of a number of strongly stained endocrine 
cells in the anterior lobe (left,  top) and the lack of cells stained in this section of the intermediate lobe (left, center). In all sections 
analyzed no or only a few weakly stained cells were observed in the intermediate lobe (results not shown). Notice also the weak 
apparently granular staining in the posterior lobe (arrow, left, bottom),  and the lack of staining when the anti-t-PA was preabsorbed 
with purified human t-PA (right). 
KRISTENSEN ET AL.  Plasminogen Activator in Endocrine Pituitary Cells  307 FIGURE 2  High magnification of rat pituitary anterior lobe stained with antiserum to t-PA absorbed with Sepharose-coupled  8SA 
(left) or purified human t-PA (right).  Note that the immunoreactive material is located in the cytoplasm of endocrine cells, often 
with a granular appearance, 
phosphate, pH 7.4, and stained immunocytochemically. The 
cellular localization of the immunoreactivity was similar to 
that found with perfused tissue, although the staining intensity 
was lower and the tissue morphology much less satisfactory 
(results not shown). No staining was found when the primary 
antibody was replaced either by preimmune IgG, TBS-BSA, 
or anti-t-PA previously absorbed with highly purified t-PA. 
No endogeneous peroxidase was observed in the perfusion- 
fixed pituitaries. 
Experiments with sequential staining of the same sections 
for t-PA followed by staining for growth hormone demon- 
strated  that  the  t-PA-immunoreactive cells  also  contained 
growth hormone immunoreactivity (Fig.  3). However, some 
cells that contained growth hormone immunoreactivity were 
negative when stained for t-PA (Fig. 3). Apparently, all t-PA- 
staining cells also contained growth hormone. 
When the staining pattern for t-PA and ACTH was com- 
pared using the sequential staining method, we observed no 
correlation (results not shown). 
Staining with anti-u-PA did not lead to detection of im- 
munoreactivity in any part of the rat pituitary gland (results 
not shown). 
Zymographic and Immunoblotting Analysis 
Zymographic analysis  of extracts of rat  pituitary glands 
showed the presence of only one plasminogen activator with 
an apparent Mr of -67,000 (Fig. 4). We previously reported 
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that the high molecular weight form of u-PA from rat urine 
under identical conditions migrates with an Mr of -48,000. 
No plasminogen activator with this electrophoretic mobility 
was detected in the rat pituitary gland extracts (Fig. 4). The 
plasminogen activator of Mr ~67,000 was removed from the 
extracts by passage through a Sepharose-column coupled with 
anti-human t-PA IgG (Fig. 4). Furthermore, analysis of the 
same pituitary gland extracts with SDS PAGE followed by 
immunoblotting with the use of anti-human  t-PA  showed 
one stainable band, with an Mr ~  67,000, similar to that of 
human t-PA (Fig. 5). 
DISCUSSION 
The findings that  (a) the  apparent Mr  of the plasminogen 
activator of rat pituitary gland extracts was  similar to that 
previously reported for human t-PA (-67,000, reference 31), 
(b) it binds to anti-human t-PA IgG, and (c) a protein band 
with a similar electrophoretic mobility is stained with anti- 
human t-PA IgG in immunoblotting indicate that this plas- 
minogen activator is t-PA and that the anti-human t-PA IgG 
cross-reacts with  rat t-PA.  The latter conclusion is  further 
supported by the fact that staining of other rat tissues  with 
anti-human  t-PA  showed immunoreactivity in  endothelial 
cells of veins and other blood vessels (results not shown) in a 
manner comparable to that reported for human tissues with 
the same antibodies (26). 
Staining and absorption controls clearly demonstrated that FIGURE 3  Sequential  staining for t-PA (/eft) and growth hormone (right).  After staining for t-PA the reaction product and antibodies 
were eluted and the section was stained for growth hormone (see Materials and Methods).  Note that all the t-PA-containing cells 
contain growth hormone (straight arrows) but that a few apparently t-PA-negative cells contain growth hormone immunoreactivity 
(curved arrow). 
FIGURE 4  Zymographic analysis of  extracts 
of rat pituitary glands. Pituitary  glands of six 
rats were extracted and 25 t~l of the extract 
was applied to each of two Sepharose col- 
umns coupled with either 2 mg anti-t-PA IgG 
(lane a) or 2 mg preimmune IgG (lane b) and 
equilibrated  with TBS. The columns were de- 
veloped with TBS and the run-through and 
wash  fractions  (2.4  ml)  were collected, di- 
alyzed against 0.1% (wt/vol) SDS, and freeze- 
dried. The precipitate was dissolved in sample buffer without SDS 
and subjected  to SDS PAGE followed by zymography for plasmin- 
ogen activators for 4 h at 37°C. A zymogram of the original pituitary 
extract was identical to that shown in  lane b.  No lysis was seen 
when plasminogen was omitted from the agarose gel (results not 
shown). The localization of marker proteins stained by Coomassie 
Blue are indicated. 
the staining of the pituitary gland with anti-t-PA was due to 
immunological binding of the  purified IgG preparation  to 
tissue components. The results of the absorption experiments 
with the highly pure t-PA (detection limit for contaminating 
proteins was -5%  as evaluated by SDS PAGE followed by 
Coomassie Blue staining),  obtained by affinity chromatogra- 
phy with a monoclonal antibody, make it unlikely that the 
staining is due to contaminating antibodies. Furthermore, the 
finding  that  the  immunoblotting analysis  of the  pituitary 
gland extracts revealed that only one band was stained with 
anti-t-PA, and the fact that this band had an electrophoretic 
mobility similar to that of  human t-PA, makes it unlikely that 
the staining or part of the staining is due to cross-reaction of 
the anti-t-PA IgG with molecules different from rat t-PA. We 
thus find it very likely that the staining demonstrated in this 
study  was  due  to  the  presence  of authentic  t-PA.  These 
findings represent the first direct evidence for the presence of 
t-PA in (and probably production by) cell types other than 
endothelial cells (26,  36) in the intact normal organism and 
therefore point to t-PA's having functions other than partici- 
paring in thrombolysis (see below and reference 4 for a further 
discussion). 
Our sequential staining experiments showed that the cells 
containing t-PA immunoreactivity  also contained growth hor- 
mone immunoreactivity and that the t-PA-containing cells 
constitute a  large subpopulation of the somatotrophs. After 
elution of the t-PA staining, each section was stained again 
with swine anti-rabbit immunoglobulin and  rabbit peroxi- 
dase-antiperoxidase complexes, and only sections completely 
devoid of reaction were stained for the second antigen. Fur- 
thermore, the finding that some t-PA-negative ceils display 
growth  hormone immunoreactivity, the  finding of a  more 
intensive staining with  anti-human  growth  hormone anti- 
serum,  and  the  lack  of correspondence when  anti-ACTH 
antiserum  was  employed all  make  it  improbable  that  the 
antibody elution was insufficient. 
The lack of detectable u-PA immunoreactivity was not due 
to a lack of cross-reaction of the anti-mouse u-PA IgG with 
rat u-PA, because such a cross-reaction has been demonstrated 
(28).  It is, however, possible that the anti-mouse u-PA IgG 
could not stain rat u-PA under the conditions used, and we 
therefore stained rat kidney with the anti-u-PA IgG. These 
experiments revealed a distribution of u-PA immunoreactiv- 
ity in epithelial cells of proximal and distal kidney tubules 
(results  not  shown)  similar  to  that  previously reported in 
mouse kidney (25), indicating that these antibodies can stain 
rat u-PA. The lack of detectable u-PA immunoreactivity in 
the rat pituitary gland agrees with similar results previously 
reported for the mouse pituitary gland (25). 
The presence of plasminogen activators of nondetermined 
type in endocrine tissue was first noted in extracts of human 
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tracts of rat pituitary glands. 25/zl of the extract (see legend to Fig. 
4) was applied to each of three lanes (?a-/c). Purified human t-PA 
(2.5 ng) was applied to each of three other lanes (2a-2c).  After SDS 
PAGE the proteins were transferred  by electrophoresis to nitrocel- 
lulose sheets. The paper was cut longitudinally and stained  immu- 
nocytochemicaily using anti-t-PA lgG (10/~g/ml)  previously passed 
through Sepharose columns coupled with BSA (lanes a) or purified 
human t-PA (lanes b), or using preimmune IgG (10/~g/ml)  (lanes c). 
The localization of marker proteins stained by Amido black (21) are 
indicated. 
pituitary, thyroid, and adrenal glands (37).  By overlaying of 
tissue  sections with  a  fibrin  layer containing  plasminogen, 
plasminogen activator of a nondetermined type was demon- 
strated in mouse hypothalamus and amygdala (22).  Isolated 
islets  of Langerhans,  maintained in  culture,  were found to 
secrete  plasminogen  activator,  and  this  secretion  could  be 
modulated by a  number of substances known to modulate 
the secretion of insulin (23). 
It was recently reported that  rat  pituitary gland  cells in 
culture secreted both u-PA and t-PA, and it was demonstrated 
that the total plasminogen activator activity in the cell cultures 
could be modulated by a number of biological effector mol- 
ecules, such as different hormones (24). That report points to 
subpopulations of the prolactin-, LH-, and ACTH-containing 
cells as producers of plasminogen activators, at least in cell 
culture. The present results apparently disagree, as we found 
virtually all t-PA-containing cells to contain growth hormone 
immunoreactivity, and because we did not observe any cor- 
relation between the presence of t-PA and ACTH immuno- 
reactivity. Furthermore, our results apparently disagree as to 
the presence of u-PA in the pituitary gland cells.  This latter 
apparent discrepancy was not due to the fact that female rats 
were used in the previous study and male rats in the present 
study,  because immunocytochemical  staining  of  pituitary 
glands from female rats did not reveal any detectable u-PA 
immunoreactivity (results not shown). The differences in the 
findings concerning u-PA in the two studies might however 
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be explained by cultured  cells' not  necessarily being repre- 
sentative of  the corresponding cell types in the intact organism 
with respect to production and release of plasminogen acti- 
vators. This could be due to a selection of cells taking place 
when cultures are established and to differences in the pres- 
ence of regulatory factors between the microenvironment of 
cells in the intact organism and in culture (see references 4 
and 25 for further discussion). Note also that u-PA may have 
been present in the intact pituitary gland in the rat (and in 
the mouse; see reference 25) in amounts below the detection 
limit, and that our results determine the presence of a certain 
amount of the respective plasminogen activators in the cells 
at the time of fLxation and do not necessarily reflect the site 
or amount of activator production. 
Many data now indicate that processing of prohormones to 
polypeptide hormones takes place in the secretion granules of 
endocrine cells and neurons, and both serine and thiol pro- 
teases, among other enzymes, have been implicated in  the 
posttranslational proteolysis (38-42).  It has previously been 
proposed  that  plasminogen  activators  play a  role  in  these 
processes (22-24). Our results support this notion with respect 
to the somatotrophs of the pituitary gland and point to t-PA's 
and not u-PA's being the activator possibly involved in post- 
translational processing in these cells. 
At  present the  only known  natural  substrate  for t-PA is 
plasminogen, which is converted to plasmin by a cleavage of 
an arginine-valine bond (43).  t-PA could be involved in the 
processing of prohormones either by a direct catalytic activity 
on the respective prohormones or by activation of plasmino- 
gen to plasmin, which in turn could catalyze the processing. 
Alternative possibilities are that t-PA or plasmin could partici- 
pate in  prohormone conversion by activation of processing 
enzymes present  in  a  proenzyme form.  To  evaluate these 
possibilities further studies are needed of the localization of 
t-PA on the  electron  microscopic level and  of the  possible 
presence of plasminogen in the t-PA immunoreactive cells. 
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